Health CarePharmaceuticals and Biotechnology
  • Price (USD)146.92
  • Today's Change-1.43 / -0.96%
  • Shares traded213.00
  • 1 Year change-15.11%
  • Beta1.6983
Data delayed at least 15 minutes, as of Mar 28 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.

  • Revenue in USD (TTM)19.26bn
  • Net income in USD8.36bn
  • Incorporated2016
  • Employees3.90k
  • Location
    Moderna Inc200 Technology SqCambridge 02139-3578United StatesUSA
  • Phone+1 (617) 714-6500
  • Fax+1 (617) 583-1998
  • Websitehttps://www.modernatx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRNA:NSQ since
OriCiro Genomics KKDeal completed04 Jan 202304 Jan 2023Deal completed-17.92%85.00m
Data delayed at least 15 minutes, as of Mar 28 2023 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
DuPont de Nemours Inc13.02bn1.01bn31.89bn23.00k34.581.2014.522.452.0112.0926.0658.000.2993.815.57565,956.502.440.21932.740.288935.4534.768.151.442.405.800.2301840.003.592.21-12.68---27.682.98
Iqvia Holdings Inc14.41bn1.09bn35.34bn86.00k33.206.1215.832.455.725.7275.6031.040.5761--5.27167,558.104.412.385.632.9434.8934.327.654.64--4.530.68860.003.868.2312.9428.5312.80--
Seagen Inc1.96bn-610.31m37.99bn3.26k--13.51--19.36-3.30-3.3010.6315.030.53081.314.40602,706.40-16.51-7.68-20.32-8.9479.1085.29-31.10-14.452.90--0.00--24.6532.409.51--21.91--
Moderna Inc19.26bn8.36bn56.66bn3.90k7.362.966.512.9419.9619.9646.3149.670.76254.538.454,939,231.0033.1038.5945.8558.0571.88--43.4148.842.54--0.05310.004.29147.88-31.47--46.94--
Zoetis Inc8.08bn2.11bn76.48bn13.80k36.7217.3829.699.474.494.4917.199.500.56061.146.88585,507.3014.6514.0617.6916.5169.7869.2926.1325.021.6312.680.642224.623.918.773.7814.4621.2124.14
Vertex Pharmaceuticals Incorporated8.93bn3.32bn80.53bn4.80k24.445.7923.219.0212.8212.8234.4754.130.56552.666.931,860,563.0021.0419.9224.8823.8187.9087.7137.2033.694.6672.860.030.0017.9129.1241.8466.04-4.63--
Data as of Mar 28 2023. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD

Institutional shareholders

34.46%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Dec 202244.79m11.66%
The Vanguard Group, Inc.as of 31 Dec 202225.91m6.75%
BlackRock Fund Advisorsas of 31 Dec 202217.29m4.50%
SSgA Funds Management, Inc.as of 31 Dec 202214.30m3.72%
Coatue Management LLCas of 31 Dec 20226.39m1.66%
Geode Capital Management LLCas of 31 Dec 20226.17m1.61%
Th�l�me Partners LLPas of 31 Dec 20225.86m1.53%
Wellington Management Co. LLPas of 31 Dec 20224.28m1.11%
Capital Research & Management Co. (World Investors)as of 31 Dec 20223.90m1.02%
Norges Bank Investment Managementas of 31 Dec 20223.50m0.91%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.